According to the testing laboratory, the FoundationOne CDx (F1CDx) is a companion diagnostic test used to identify patients who may benefit from treatment with Food and Drug Administration (FDA)-approved targeted therapies. Additionally, the test is intended to provide tumor mutation profiling that includes the screening of biomarkers without companion diagnostic claims. This report evaluates the analytical validity, clinical validity, and clinical utility of the F1CDx test.

If you have a Hayes login, click here to view the full report on the Knowledge Center.